Abstract 2602
Background
The CONCORD programme initiated world-wide surveillance of trends in population-based cancer survival in 2015. The third cycle (CONCORD-3) covered 18 cancers, including brain tumours. Data for 656,659 adults (15-99 years) diagnosed with a brain tumour were provided by 286 registries in 59 countries. For adults diagnosed during 2010-2014, 5-year net survival from all brain tumours combined varied between 15% and 42%. We will present detailed comparison of survival trends for gliomas defined by anatomic location, morphology and WHO grade.
Methods
We will present the numbers of adults diagnosed with a glioma and the sub-type distribution by continent. We will estimate net survival up to 5 years, using the unbiased Pohar Perme estimator. Net survival is the probability that patients survive their cancer until a given time since diagnosis, after controlling for competing risks of death (background mortality) by age, sex, country and calendar year.
Results
Data were obtained for 545,184 adults. Glioblastoma was the most common morphology (57%). Astrocytic, oligodendroglial and oligo-astrocytic tumours specified as WHO grade I-III made up 21% of all gliomas, while glioma not otherwise specified (NOS) and astrocytoma NOS made up 15%. Rarer tumours, such as oligodendroglioma, fibrillary astrocytoma, pilocytic astrocytoma, mixed glioma, anaplastic oligodendroglioma and anaplastic astrocytoma made up less than 10% of gliomas in all continents. The frequency of glioblastoma was 58% or higher in Europe, North America and Oceania, 53% in Africa and around 45% in Asia and Central and South America. The frequency of astrocytoma NOS was lowest in Europe, North America and Oceania (below 9%) and highest in Central and South America (22%).
Conclusions
The distribution of gliomas varies around the world. The differential was the frequency of unspecified morphologies, which may be partly attributable to diagnostic capacity. We will assess the extent to which disparities in morphology contribute to worldwide variation in survival from adult brain tumours. When comprehensive survival analyses are available, this project is expected to become the reference for international comparison of brain tumour survival, to help inform national cancer control plans.
Clinical trial identification
Legal entity responsible for the study
London School of Hygiene and Tropical Medicine.
Funding
Children with Cancer UK.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract